Iomeron (Iomeprol)

Iomeprol is a high‑density, non‑ionic iodine compound that absorbs X‑rays more strongly than surrounding tissues. When injected into the vascular system or cerebrospinal fluid, it increases X‑ray attenuation, creating a contrast between blood‑filled structures and adjacent organs, thereby improving the delineation of vessels, organs, and pathological lesions on radiographic images.

The specific dose of Iomeron is determined by the prescribing physician based on the type of imaging study, patient weight, renal function, and the required level of contrast enhancement. Dosing guidelines are provided in the product’s prescribing information and must be individualized for each patient.

Safety data for iomeprol in pregnancy and lactation are limited, and the product is generally classified as contraindicated or to be used only if the potential diagnostic benefit outweighs the possible risk to the fetus or infant. Healthcare providers should evaluate the risk‑benefit profile before administering Iomeron to pregnant or nursing patients.

To place an order, submit an enquiry on the Iomeron product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Iomeron (iomeprol) is a non‑ionic, low‑osmolality iodinated contrast medium, offering a favorable safety profile compared with older high‑osmolality agents that are associated with higher rates of discomfort and adverse reactions. Compared with other low‑osmolality agents, its physicochemical properties are similar, and choice often depends on institutional preference, cost, and specific imaging protocols.

Iomeron should be stored at controlled room temperature, preferably below 25 °C, in its original sealed container. Protect the solution from direct sunlight, moisture, and freezing. Before use, inspect the vial for particulate matter or discoloration and allow the solution to reach room temperature if it has been refrigerated during transport.

Iomeron is supplied as a sterile solution for injection and is administered intravenously, intra‑arterially, or intrathecally by a qualified healthcare professional. The injection is typically performed using a power injector or manual bolus, following aseptic technique and the dosing instructions provided in the prescribing information.

The most serious risks include severe allergic or anaphylactoid reactions, contrast‑induced nephropathy leading to acute kidney injury, and hemodynamic changes such as hypotension or arrhythmias. Patients with known iodine allergy, impaired renal function, or uncontrolled thyroid disease should be closely monitored, and emergency measures must be readily available.

Iomeron is contraindicated in patients with a documented severe hypersensitivity to iomeprol or any iodinated contrast media, as well as in individuals with uncontrolled hyperthyroidism where an iodine load could exacerbate the condition. Caution is also advised for patients with severe renal impairment, as the agent is eliminated renally.